Summit Securities Group’s Epizyme, Inc EPZM Stock Holding History

Summit Securities Group’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-12	Closed	–	–	614
2013 Q3	$0	Buy	+12	New	+$406	﹤0.01%	584

Other funds holding EPZM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Summit Securities Group's EPZM Position: Q4 2013 in Review

Summit Securities Group sold out of Epizyme, Inc (EPZM) in Q4 2013, closing a stake of 12 shares.

Summit Securities Group first reported a position in EPZM in Q3 2013 and held it in 1 quarter. The position peaked at $0 in Q3 2013. 60 funds tracked by Wall St. Rank hold EPZM as of Q4 2013.

Summit Securities Group reported no remaining Epizyme, Inc position as of Q4 2013 after selling out during the quarter.
Summit Securities Group sold 12 Epizyme, Inc shares in Q4 2013.
Summit Securities Group first reported a position in Epizyme, Inc in Q3 2013 and held it in 1 quarter.
Summit Securities Group's Epizyme, Inc position peaked at $0 in Q3 2013.
60 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2013.

Based on Summit Securities Group's 13F filing for Q4 2013, filed 13 Feb 2014.